TetraGenetics is had been a drug discovery company using proprietary technology (TetraExpress™) to discover large molecule drugs targeting ion channel membrane proteins associated with many human diseases. Supporting those seeking a cost-effective alternative platform technology for the production of genetically engineered proteins, in September 2021, TertraGenetics was acquired AbCellera whereby to enhancing the latter's capabilities to generate antibodies against high-value targets Having ties to Cornell with facilities in Ithaca NY and in Arlington, MA, Tetragenetic's drug discovery focus organized around discovery and development of first-in-class biologic medicines for autoimmune diseases, oncology and pain. The company" drug discovery platform (TetraExpress™) identified antibodies targeting ion channels and other transmembrane proteins. TetraGenetics had been actively building a proprietary drug pipeline and working collaboratively with major biotech companies for antibody drug discovery. Structured to address the needs of those seeking a cost-effective alternative platform technology for the production of genetically engineered proteins, the firm's technology is particularly well suited to the production of eucaryotic membrane and secretory proteins that are difficult to express in conventional systems. Such proteins include vaccine antigens, monoclonal antibodies, and a variety of therapeutic proteins for the treatment and prevention of human and animal disease. The firm's bio-pharmaceutical platform is designed to develop novel therapeutics for autoimmune diseases. The company's platform develops proprietary technology that helps in the rapid production of properly folded and functional ion channel proteins in membrane preparations and in purified form for use in antibody discovery and small molecule screening programs, enabling physicians to access treatments for ion channel related autoimmune diseases and pain management.
